NCT07149857 A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel Status RECRUITING Phase PHASE2
NCT06577025 A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06550895 A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05347485 A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma Status COMPLETED Phase PHASE2
NCT05257083 A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05201781 A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel Status RECRUITING Phase PHASE4
NCT04923893 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04181827 A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE3